Efficacy of human papillomavirus vaccines in the prevention of male genital diseases: a systematic review

IF 3.7 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International Pub Date : 2025-03-11 DOI:10.1111/bju.16692

Mehdi Kardoust Parizi, Nirmish Singla, Akihiro Matsukawa, Ichiro Tsuboi, Stefano Mancon, Marcin Miszczyk, Piotr Chlosta, Shahrokh F. Shariat

{"title":"Efficacy of human papillomavirus vaccines in the prevention of male genital diseases: a systematic review","authors":"Mehdi Kardoust Parizi, Nirmish Singla, Akihiro Matsukawa, Ichiro Tsuboi, Stefano Mancon, Marcin Miszczyk, Piotr Chlosta, Shahrokh F. Shariat","doi":"10.1111/bju.16692","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To evaluate the results of randomised controlled trials (RCTs) regarding the efficacy of human papillomavirus (HPV) vaccination in preventing male genital-related diseases.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic search of English language literature using PubMed, Scopus, and Cochrane Library was performed in April 2024 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Evidence from four RCTs (including 7008 male participants) support the efficacy of the quadrivalent HPV vaccine in preventing genital warts and persistent HPV infection in HPV-naïve men. The low incidence of male genital malignancies in the control groups of the reported studies lead to underpowered evidence. However, vaccination leads to durable protection with a long-term follow-up of 10 years showing efficacy of 91.8% to prevent HPV 6-, 11-, 16-, or 18-related external genital lesions (EGLs) in HPV-naïve subjects. Additionally, the quadrivalent vaccine seems to effectively reduce the detection of DNA from all four HPV types.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In summary, early quadrivalent HPV vaccination demonstrates efficacy in preventing HPV infection and EGLs in males. Well controlled prospective studies are needed to confirm the long-term efficacy, specifically in cancer prevention, in all men and specific subject subgroups, and to identify the targeted population who is most likely to benefit from early vaccination.</p>\n </section>\n </div>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"135 6","pages":"902-907"},"PeriodicalIF":3.7000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bju.16692","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJU International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bju.16692","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

To evaluate the results of randomised controlled trials (RCTs) regarding the efficacy of human papillomavirus (HPV) vaccination in preventing male genital-related diseases.

Methods

A systematic search of English language literature using PubMed, Scopus, and Cochrane Library was performed in April 2024 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol.

Results

Evidence from four RCTs (including 7008 male participants) support the efficacy of the quadrivalent HPV vaccine in preventing genital warts and persistent HPV infection in HPV-naïve men. The low incidence of male genital malignancies in the control groups of the reported studies lead to underpowered evidence. However, vaccination leads to durable protection with a long-term follow-up of 10 years showing efficacy of 91.8% to prevent HPV 6-, 11-, 16-, or 18-related external genital lesions (EGLs) in HPV-naïve subjects. Additionally, the quadrivalent vaccine seems to effectively reduce the detection of DNA from all four HPV types.

Conclusion

In summary, early quadrivalent HPV vaccination demonstrates efficacy in preventing HPV infection and EGLs in males. Well controlled prospective studies are needed to confirm the long-term efficacy, specifically in cancer prevention, in all men and specific subject subgroups, and to identify the targeted population who is most likely to benefit from early vaccination.

Abstract Image

查看原文本刊更多论文

人乳头瘤病毒疫苗预防男性生殖器疾病的疗效：系统综述

评价接种人乳头瘤病毒（HPV）预防男性生殖相关疾病的随机对照试验（RCTs）的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BJU International 医学-泌尿学与肾脏学

CiteScore

9.10

自引率

4.40%

发文量

262

审稿时长

1 months

期刊介绍： BJUI is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. Every issue gives invaluable practical information in the form of original articles, reviews, comments, surgical education articles, and translational science articles in the field of urology. BJUI employs topical sections, and is in full colour, making it easier to browse or search for something specific.